Massachusetts-based Sarepta Therapeutics disclosed that although the FDA reiterated its skepticism regarding data surrounding a drug to slow the progression of Duchenne muscular dystrophy, the agency has detailed a potential path forward for the drug and indicated a willingness to consider it for accelerated approval. Louis Kunkel, professor of pediatrics at Boston Children’s Hospital, is quoted.
